The Limited Times

Now you can see non-English news...

Following the exposures in "Israel Today": 6 expensive drugs for severely ill patients - enter the basket | Israel today

2020-01-19T01:12:59.851Z


health


Serious disease drugs will be included in the basket by 2020 • CTX, SMA and family amyloidosis patients will receive assistance • The state will now support HIV prevention and put into the meningitis vaccine • In addition, rare blood disease patients will not have to undergo splenectomy for drug treatment

  • New Drug Basket Treatments // Photo Illustration: GettyImages

The ongoing exposures in "Israel Today" to hospital struggles have resulted in 6 new drugs entering the drug basket. Some are very expensive, and are for rare and serious diseases.

The most commonly prescribed drug is the most expensive drug in the world - NIS 7.6 million. In August 2019, the battle for parents of Israeli babies diagnosed with the rare SMA muscular dystrophy, which needs the new genetic drug ZOLGENSMA, was unveiled. The drug is manufactured by the drug company Abaxis (AVEXIS) and is owned by the pharmaceutical giant Novartis (NOVARTIS). The drug is marketed in Israel by TruMed.

The Drug Basket Committee has submitted its recommendation to Health Minister Litzman // Photo: Ami Shamir

Following the release of "Israel Today", the Pharmaceutical Basket Committee canceled the condition for splenectomy to receive two new drugs for the rare ITP blood disease patients. So far under the basket's conditions, about 150 patients with rare blood disease could receive one of two expensive drugs to help with their disease, only under the condition of the spleen.

The two drugs used to treat the disease are the injectable (NPLATE) drug, manufactured by Amgen Pharmaceuticals and imported into the country by Madison, and the herbal drug (REVOLADE), administered by Novartis. The drugs have now been budgeted at about NIS 12 million for about 170 patients.

Exposure to "Israel Today" has led to the introduction of a cure for the inherited and rare genetic amyloidosis genetic disease that causes severe damage to the nervous system, heart, digestive system, kidneys, eyes and brain. The drug that has now entered the basket is the ONPATTRO drug from the ALNYLAM drug company, which is imported into the country by Madison.

In November 2019, "Israel Today" revealed that Dr. Amir Dori, a senior neurologist at Sheba in Tel Hashomer, warned the Committee on Drugs and the Ministry of Health that "six patients I treat who are deteriorating under existing drug treatment will die without urgent inclusion in the basket of the new drug The drug was put in the basket.

Another drug that was added to the basket following the exposure in Israel today is a LEADIANT drug, designed for a rare and incurable genetic disease (CTX disease). The approval was granted after the appeal of senior neurologists, who called on the Hessel Committee to approve the drug.

The drug basket was first introduced to prevent HIV-causing HIV infection, after several years in which senior ministry officials opposed it and criticized it severely. In September 2018, a comprehensive investigation was published in the "Shabbat" supplement, in which difficult findings were made about the Ministry of Health and HMO's neglect of bringing life-saving treatment to the drug basket. The bexarox vaccine (BEXSERO) was also placed in a limited group of patients. The vaccine is the first in the world approved to prevent meningitis-induced infections from the infectious and deadly bacterium from Ningococcus B. The vaccine's introduction was unveiled in "Israel Today" in August 2018.

Source: israelhayom

All life articles on 2020-01-19

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.